# Cellzome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellzome

- Industry: Pharmaceuticals
- Headquarters: Heidelberg, Germany
- Website: www.cellzome.com
- Total disclosed funding: $63M
- Latest round: Series C (Mar 18, 2003)
- Investors on record: 11

## About

Cellzome, is based in Germany and is a drug discovery company, engages in the discovery, development, and commercialization of kinase-targeted drugs for the treatment of inflammatory diseases.

## Funding rounds

- Series C, Mar 18, 2003, $33M — Advent International, Atlas Venture, Index Ventures, Invesco, Sofinnova Investments, Heidelberg Innovation Funds Management, SGAM Private Equity, Astellas Venture Management, Schroder Ventures, Biofrontier Partners
- Series B, Mar 1, 2001, $30M — Advent International, Schroders Capital, Atlas Venture, Index Ventures, Sofinnova Investments, Heidelberg Innovation Funds Management

## Investors

- Advent International (https://capitalatlas.ai/funds/advent-international) — Series B, Series C
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B, Series C
- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series B, Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B, Series C
- Heidelberg Innovation Funds Management (https://capitalatlas.ai/funds/heidelberg-innovation-funds-management) — Series B, Series C
- Invesco (https://capitalatlas.ai/funds/invesco) — Series C
- SGAM Private Equity (https://capitalatlas.ai/funds/sgam-private-equity) — Series C
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series C
- Schroder Ventures (https://capitalatlas.ai/funds/schroder-ventures) — Series C
- Biofrontier Partners (https://capitalatlas.ai/funds/biofrontier-partners) — Series C